F-star, InvoX extend end date of merger agreement to March 3

According to a regulatory filing, F-star Therapeutics, InvoX Pharma Limited, and Fennec Acquisition on February 22 entered into Amendment No. 7 to the Agreement and Plan of Merger, dated as of June 22, 2022, and as amended, by and among the Parties and Sino Biopharmaceutical Limited, a company organized under the laws of the Cayman Islands, as "Guarantor." Capitalized terms used in this Current Report on Form 8-K without being defined herein shall have the same meanings ascribed to them in the Merger Agreement. The purpose of Amendment No. 7 is to extend the End Date of the Merger Agreement in order to provide additional time for the Parties to finalize an agreement with the Committee on Foreign Investment in the United States and to complete the ongoing tender offer whose expiration date has been extended to March 3, 2023, unless further extended. The Parties believe they are in the late stages of the approval process for a definitive agreement necessary to remove CFIUS’s Interim Order and allow the transaction to close. However, there can be no assurances that the Parties will reach a final agreement with CFIUS.